SIM
PGNX

Spark Investment Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Spark Investment Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-41,600
Closed -$185K – 612
2013
Q2 		$185K Buy
+41,600
New +$187K 0.05% 348

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Spark Investment Management's PGNX Position: Q3 2013 in Review

Spark Investment Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2013, closing a stake of 41,600 shares — an estimated $185K sold.

Spark Investment Management first reported a position in PGNX in Q2 2013 and held it in 1 quarter. The position peaked at $185K in Q2 2013. 83 funds tracked by Wall St. Rank hold PGNX as of Q3 2013.

  • Spark Investment Management reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2013 after selling out during the quarter.
  • Spark Investment Management sold 41,600 Progenics Pharmaceuticals Inc shares in Q3 2013, an estimated $185K.
  • Spark Investment Management first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 1 quarter.
  • Spark Investment Management's Progenics Pharmaceuticals Inc position peaked at $185K in Q2 2013.
  • 83 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2013.

Based on Spark Investment Management's 13F filing for Q3 2013, filed 13 Nov 2013.